CN103520098A - 恩诺沙星兽用长效注射剂的制备方法 - Google Patents
恩诺沙星兽用长效注射剂的制备方法 Download PDFInfo
- Publication number
- CN103520098A CN103520098A CN201310528301.7A CN201310528301A CN103520098A CN 103520098 A CN103520098 A CN 103520098A CN 201310528301 A CN201310528301 A CN 201310528301A CN 103520098 A CN103520098 A CN 103520098A
- Authority
- CN
- China
- Prior art keywords
- preparation
- enrofloxacin
- injection
- saib
- ethyl oleate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007924 injection Substances 0.000 title claims abstract description 54
- 238000002347 injection Methods 0.000 title claims abstract description 54
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229960000740 enrofloxacin Drugs 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title abstract description 4
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 claims abstract description 56
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims abstract description 27
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims abstract description 27
- 229940093471 ethyl oleate Drugs 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 27
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims abstract description 26
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims abstract description 25
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960002903 benzyl benzoate Drugs 0.000 claims abstract description 16
- 239000004359 castor oil Substances 0.000 claims abstract description 3
- 235000019438 castor oil Nutrition 0.000 claims abstract description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 3
- 229940074928 isopropyl myristate Drugs 0.000 claims abstract 2
- PZJWYUDBXNNVLZ-UHFFFAOYSA-N 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydrochloride Chemical compound Cl.C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 PZJWYUDBXNNVLZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000003921 oil Substances 0.000 claims description 15
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- QSHVAZMOLNGWSY-UHFFFAOYSA-N 3-butyl-4-methoxyphenol Chemical group CCCCC1=CC(O)=CC=C1OC QSHVAZMOLNGWSY-UHFFFAOYSA-N 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 90
- 230000000694 effects Effects 0.000 abstract description 4
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 abstract 2
- 239000001797 sucrose acetate isobutyrate Substances 0.000 abstract 2
- 239000002612 dispersion medium Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 21
- 239000002245 particle Substances 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000004576 sand Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000084 colloidal system Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- -1 Benzyl Benzoate ester Chemical class 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010022079 Injection site irritation Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
采血时间 | 不同给药剂量的血浆药物浓度μg/ml |
h | 14mg/kgb.w. | 20mg/kgb.w. |
1 | 0.98 | 1.23 |
3 | 1.23 | 2.05 |
6 | 1.97 | 2.46 |
12 | 2.06 | 2.18 |
24 | 1.32 | 1.72 |
48 | 0.56 | 1.21 |
72 | 0.17 | 0.83 |
96 | 0.07 | 0.31 |
120 | 未检出 | 0.10 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310528301.7A CN103520098A (zh) | 2013-10-30 | 2013-10-30 | 恩诺沙星兽用长效注射剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310528301.7A CN103520098A (zh) | 2013-10-30 | 2013-10-30 | 恩诺沙星兽用长效注射剂的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103520098A true CN103520098A (zh) | 2014-01-22 |
Family
ID=49922690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310528301.7A Pending CN103520098A (zh) | 2013-10-30 | 2013-10-30 | 恩诺沙星兽用长效注射剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103520098A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107982214A (zh) * | 2016-10-26 | 2018-05-04 | 华中农业大学 | 兽用恩诺沙星固体脂质纳米混悬液及其制备方法 |
CN108578366A (zh) * | 2018-05-25 | 2018-09-28 | 四川伴农动保生物技术有限公司 | 一种非水溶剂长效恩诺沙星注射液及其制备工艺 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1517090A (zh) * | 2003-01-20 | 2004-08-04 | 王玉万 | 含抗菌药物的兽用混悬注射剂或乳剂 |
US20060034926A1 (en) * | 2003-03-20 | 2006-02-16 | Kristine Fraatz | Controlled release system |
CN101690713A (zh) * | 2009-09-28 | 2010-04-07 | 洛阳普莱柯生物工程有限公司 | 一种喹诺酮注射液的制备方法 |
-
2013
- 2013-10-30 CN CN201310528301.7A patent/CN103520098A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1517090A (zh) * | 2003-01-20 | 2004-08-04 | 王玉万 | 含抗菌药物的兽用混悬注射剂或乳剂 |
US20060034926A1 (en) * | 2003-03-20 | 2006-02-16 | Kristine Fraatz | Controlled release system |
CN101690713A (zh) * | 2009-09-28 | 2010-04-07 | 洛阳普莱柯生物工程有限公司 | 一种喹诺酮注射液的制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107982214A (zh) * | 2016-10-26 | 2018-05-04 | 华中农业大学 | 兽用恩诺沙星固体脂质纳米混悬液及其制备方法 |
CN107982214B (zh) * | 2016-10-26 | 2021-02-05 | 华中农业大学 | 兽用恩诺沙星固体脂质纳米混悬液及其制备方法 |
CN108578366A (zh) * | 2018-05-25 | 2018-09-28 | 四川伴农动保生物技术有限公司 | 一种非水溶剂长效恩诺沙星注射液及其制备工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101922752B1 (ko) | 사이클로덱스트린 및 소수성 약물을 포함하는 주사용 약제학적 조성물을 보존하는 방법 | |
CN103655459A (zh) | 一种多功能微乳凝胶制剂及其制备工艺 | |
CN103536530A (zh) | 盐酸多西环素长效注射剂及制备方法 | |
CN101690713B (zh) | 一种喹诺酮注射液的制备方法 | |
WO2013143300A1 (zh) | 氟维司群或其衍生物缓释制剂及其制备方法 | |
CN102119923B (zh) | 一种兽用抗菌油、水双混悬型注射用乳剂及其制备方法 | |
CN103550149A (zh) | 含抗寄生虫药物长效注射剂的制备技术 | |
CN103550150B (zh) | 改进的含二甲基硅油的注射剂 | |
CN103520098A (zh) | 恩诺沙星兽用长效注射剂的制备方法 | |
CN102429918A (zh) | 一种含有氟苯尼考和茶皂素的药物组合物及其制备方法 | |
CN101623255B (zh) | 一种青蒿琥酯纳米乳药物组合物及其制备方法 | |
CN105030760A (zh) | 稳定医药组合物 | |
CN103705454A (zh) | 含盐酸沃尼妙林/泊洛沙姆407的油质注射剂 | |
CN103536529A (zh) | 含头孢噻呋长效注射剂及制备方法 | |
CN103520099A (zh) | 含有效成份为沃尼妙林的长效注射剂 | |
CN102920656A (zh) | 一种莫西沙星纳米乳及其制备方法 | |
CN103550152A (zh) | 替米考星兽用长效注射剂制备方法 | |
CN103550148A (zh) | 延胡索酸泰妙菌素长效注射剂制备方法 | |
IL224851A (en) | An injectable non-aqueous oily product that shows effective preservation | |
CN105832744A (zh) | 一种供注射用的前列地尔冻干乳剂组合物 | |
CN103550151A (zh) | 硫酸头孢喹诺长效注射剂制备方法 | |
CN103536531A (zh) | 甲磺酸达氟沙星长效注射剂制备方法 | |
CN108430454A (zh) | 氟维司群组合物 | |
CN103520166A (zh) | 含甲磺酸达氟沙星和头孢噻呋的长效注射剂 | |
CN103520167A (zh) | 含硫酸头孢喹诺和甲磺酸达氟沙星的长效注射剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG YUWAN Effective date: 20150106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100083 HAIDIAN, BEIJING TO: 102206 CHANGPING, BEIJING |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150106 Address after: 102206 Beijing city Changping District Baishan Town East Village profile West Industrial Zone No. 535 Pro Applicant after: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. Address before: 100083 Beijing Qinghua East Road, No. 17,, 41-5-102 Applicant before: Wang Yuwan |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140122 |